Who is sponsoring NCT05651542?

NCT05651542 is sponsored by University of Washington.

What drugs are being tested in NCT05651542?

Interventions in NCT05651542: Comprehensive Self-Management Intervention, Control.

What condition does NCT05651542 study?

NCT05651542 studies Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease.

Is NCT05651542 still recruiting?

NCT05651542 is currently completed. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT05651542

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease

Completed NA Last updated 9 January 2026

What this trial tests

NA trial testing Comprehensive Self-Management Intervention in Inflammatory Bowel Diseases in 55 participants. Completed in 30 September 2025.

Timeline

14 March 2023

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	55
Start date	14 March 2023
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	1 location across United States

Drugs / interventions tested

Comprehensive Self-Management Intervention
Control

Conditions studied

Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
Ulcerative Colitis — all drugs for Ulcerative Colitis →
Crohn Disease — all drugs for Crohn Disease →

Sponsor

University of Washington

Who can join

Adults 18 to 75, any sex, with Inflammatory Bowel Diseases or Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to test the feasibility, acceptability, and preliminary efficacy of a comprehensive self-management (CSM) intervention for people with inflammatory bowel disease (IBD). The CSM-IBD intervention is an adaption of the CSM intervention initially developed for individuals with irritable bowel syndrome. The intervention has eight sessions which cover an introduction to IBD, symptom tracking, cognitive behavioral strategies, relaxation, sleep, diet, and pain management.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A Comprehensive Self-Management Intervention for Inflammatory Bowel Disease (CSM-IBD): Protocol for a Pilot Randomized Controlled Trial.
Kamp K, Clark-Snustad K, Yoo L, Winders S, et al · · 2023 · cited 6× · PMID 37285195 · DOI 10.2196/46307
Psychological interventions for treatment of inflammatory bowel disease.
Tiles-Sar N, Neuser J, de Sordi D, Baltes A, et al · · 2025 · cited 5× · PMID 40243391 · DOI 10.1002/14651858.cd006913.pub3

Verify or expand the search:

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05651542 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05651542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing